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Summary
ATOH8 has previously been shown to be an iron-regulated transcription
factor, however its role in iron metabolism is not known. ATOH8 expres-
sion in HEK293 cells resulted in increased endogenous HAMP mRNA levels
as well as HAMP promoter activity. Mutation of the E-box or SMAD
response elements within the HAMP promoter significantly reduced the
effects of ATOH8, indicating that ATOH8 activates HAMP transcription
directly as well as through bone morphogenic protein (BMP) signalling. In
support of the former, Chromatin immunoprecipitation assays provided
evidence that ATOH8 binds to E-box regions within the HAMP promoter
while the latter was supported by the finding that ATOH8 expression in
HEK293 cells led to increased phosphorylated SMAD1,5,8 levels. Liver
Atoh8 levels were reduced in mice under conditions associated with
increased erythropoietic activity such as hypoxia, haemolytic anaemia, hyp-
otransferrinaemia and erythropoietin treatment and increased by inhibitors
of erythropoiesis. Hepatic Atoh8 mRNA levels increased in mice treated
with holo transferrin, suggesting that Atoh8 responds to changes in plasma
iron. ATOH8 is therefore a novel transcriptional regulator of HAMP, which
is responsive to changes in plasma iron and erythroid activity and could
explain how changes in erythroid activity lead to regulation of HAMP.
Keywords: ATOH8, HAMP, iron, erythropoiesis, pSMAD1,5,8.
Erythropoiesis is essential for life and is by far the body’s
largest user of iron, consuming almost two-thirds of the
body’s total iron. Increased erythropoietic activity has a rapid
and dramatic effect on iron metabolism, which has been well
documented (Finch, 1994). Increased erythropoietic activity
generally results in an increase in the reticulocyte fraction in
the blood with a concomitant fall in plasma iron as iron is
used up by the developing erythrocytes. Increased erythro-
poietic activity is a powerful suppressor of the iron hormone
hepcidin (HAMP) levels thereby allowing for more iron to
be made available for erythropoiesis through increased intes-
tinal iron absorption and iron release from macrophages via
regulation of the hepcidin–ferroportin axis (Nicolas et al,
2002a; Weinstein et al, 2002). The suppression of HAMP by
increased erythropoietic drive is not well understood and
occurs even in conditions where liver iron levels are high
and which would normally lead to increased HAMP levels,
such as in b-thalassaemia (Nemeth & Ganz, 2006) and
hypotransferrinaemia (Bartnikas et al, 2010). Thus the ery-
thropoietic regulator appears to be capable of overiding the
iron stores regulator of hepcidin.
Hepatic HAMP mRNA levels are regulated by three major
stimuli: (i) tissue and serum iron concentration; (ii) inflam-
matory signals and (iii) erythropoieitic activity. Regulation
of HAMP appears to occur mainly at the transcriptional
level via various response elements within the HAMP
promoter, such as the bone morphogenic proteins response
elements (BMP-REs), signal transducer and activation of
transcription 3 (STAT-3), cAMP response element binding
protein (CREB), hepatocyte nuclear factor 4 (HNF4) and
enhancer boxes (E-boxes) binding elements (Courselaud
et al, 2002; Bayele et al, 2006; Wrighting & Andrews, 2006).
The bone morphogenic protein (BMP) pathway is involved
in regulating the responses of HAMP to changes in tissue
iron via changes in hepatic BMP6 levels (Meynard et al,
2009; Ramos et al, 2011) and inflammatory signals act via
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STAT-3 resulting in activation of HAMP (Wrighting &
Andrews, 2006).
Less is known about how changes in erythropoietic activity
lead to altered hepatic HAMP levels, for example, what signals
are sensed by the liver as a result of changes in erythropoiesis
as well as the nature of the signal transduction mechanism
are unclear. Both changes in serum iron and/or release of
soluble factors from developing erythrocytes have been
evoked as potential indicators of altered erythropoietic activ-
ity. The level of plasma holo-transferrin (transferrin satura-
tion) changes rapidly as a result of altered erythropoietic
activity and is a key modulator of liver HAMP levels (Bartni-
kas et al, 2010; Li et al, 2010) and thus could be one signal,
however the signal transduction pathway leading to HAMP
regulation has not been defined. On the other hand, soluble
factors, such as growth differentiation factor 15 (GDF15) or
twisted gastrulation factor 1 (TWSG1), produced by erythroid
precursors, and bone morphogenic protein binding endothe-
lial cell precursor-derived regulator (BMPER), produced by
endothelial cells, have all been postulated to play a role in the
suppression of HAMP (Tanno et al, 2007, 2009; Patel et al,
2012) by, in most cases, inhibiting BMP signalling. However,
the roles of these molecules in the regulation of HAMP in
other forms of anaemia and conditions with altered erythro-
poiesis have not been shown. Thus the molecular basis of
erythropoietic regulation of HAMP remains unclear.
Atoh8 (or Math6) was originally identified as a distant
mammalian homologue of the drosophila neural gene Atonal
(Inoue et al, 2001). The Atoh8 mRNA encodes a basic helix
loop helix (bHLH) transcription factor and is ubiquitiously
expressed in mouse at least in embryonic tissues (Lynn et al,
2008). Atoh8 has been implicated in development of various
tissues although its physiological function remains unknown
(Lynn et al, 2008; Yao et al, 2010). Early studies had sug-
gested that knock-out of Atoh8 was embryonic lethal in mice
(Lynn et al, 2008) however, using an alternative targeting
strategy, recent work has shown that mice survive Atoh8
ablation with no obvious phenotype (Rawnsley et al, 2013).
bHLH or E-box proteins, such as ATOH8, bind to a palin-
dromic (canonical) core consensus DNA sequence 5′-CAN-
NTG-3′ known as an E-box element, where NN is usually
CG or TG (Blackwell et al, 1993). Two canonical E-boxes
have been described within the core human HAMP promoter
with the sequence 5′-CACGTG-3′ and have been shown to
bind other bHLH factors, USF1 and 2, as well as MYC and
MAX (Bayele et al, 2006). Atoh8 was first linked with iron
metabolism by Kautz et al (2008) who found that hepatic
Atoh8 mRNA levels were up-regulated in mice chronically
fed a high iron diet and down-regulated in those fed an
iron-deficient diet. Thus Atoh8 appears to be the only known
iron-regulated bHLH transcription factor. In addition we
noted that Atoh8 mRNA was strongly down-regulated in liver
expression microarrays of Tfrhpx/hpx mice (Patel et al, 2012),
a mutant with a very high degree of liver iron overload,
chronic anaemia and very low Hamp1 levels. Given that the
regulation of Atoh8 was similar to Hamp1 we hypothesized
that ATOH8 may be a transcriptional regulator of HAMP.
Here we report that ATOH8 can activate HAMP transcrip-
tion and regulate cellular levels of pSMAD1,5,8. Moreover,
Atoh8 mRNA and protein levels were regulated in mouse
liver under various conditions with altered erythropoietic
activity, providing a mechanistic link between erythropoiesis
and HAMP transcription.
Materials and methods
Animals
Hypotransferrinaemic mice (HPX or Trfhpx/hpx) were bred
and maintained as previously described (Simpson et al,
1991). Normal littermates (mixture of Trf+/+ and Trfhpx/+)
were used as controls. Hypoxia was induced by placing
7-week-old male CD1 mice in a hypobaric chamber for
24–72 h, as previously described (Raja et al, 1988); controls
of the same gender and age were maintained under normoxic
conditions. Hamp1/ mice and wild type (WT) littermates
(all female C57BL/6/129 mixed background, aged 5–7 weeks
old) were injected intraperitoneally with 60 mg/kg body
weight of neutralized phenylhydrazine (PHZ) or saline
solution twice on consecutive days as previously described
(Masaratana et al, 2011) and sacrificed 3 d after the last
injection. For erythropoietin (EPO), Carboplatin, Apo and
Holo transferrin treatments, male 6-week-old C57BL/6 mice
were switched to a diet containing <4 ppm iron (TD.80396;
Harlan Teklad, Madison, WI, USA) for 10 d to reduce the
effect of the high iron chow diet on HAMP expression as
previously described (Pak et al, 2006). Mice received intra-
peritoneal injection of either 200 units of EPO (Jansen Cilag
Ltd, High Wycombe, UK), 25 mg of carboplatin or 200
units of EPO with 25 mg of carboplatin (Sigma-Aldrich,
Gillingham, UK) dissolved in 100 ll saline on three consecu-
tive days. Control mice received 100 ll of saline. Mice were
sacrificed 24 h after the last injection. Apo and Holo trans-
ferrin (10 mg) dissolved in 100 ll of saline was injected i.p
(control mice received saline alone). Mice were sacrificed 6 h
later. Serum iron was measured with a liquid ferrozine-based
Fe reagent (Thermo Electron, Melbourne, Vic., Australia).
Tissue non-haem iron was determined as previously
described (Masaratana et al, 2012). All animal experiments
were performed under the authority of a UK Home Office
license.
Cell culture and HAMP promoter assays
HEK-293 cells were obtained from the American type culture
collection (ATCC, Teddington, UK) and cultured in Dul-
becco’s modified Eagle’s medium (DMEM; Sigma-Aldrich,
Gillingham, UK) and 10% heat-inactivated fetal bovine
serum (FBS; Sigma-Aldrich), penicillin-streptomycin and glu-
tamine (Sigma-Aldrich). Cell cultures were maintained at
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37°C under 95% air/5% CO2. Promoter assays employed
approximately 09 kb of the human HAMP promoter (WT)
cloned in the pGL3-basic luciferase reporter vector (Promega,
Southampton, UK). E-box and BMP-RE mutated versions of
this vector were kindly provided by Dr Pavle Matak (Depart-
ment of Pharmacology and Cancer Biology, Duke University
Medical Center, Durham NC, details can be found in Table
SI). Reporter constructs were co-transfected into cells with a
TK-renilla (3:1 ratio) using Fugene-6 (Roche Diagnostics,
Burgess Hill, UK). Human ATOH8 –DDK (Flag) tagged
plasmid (Origene technologies, Rockville, MD, USA) was
co-transfected along with the reporter plasmids. Lumines-
cence was detected using Dual-Luciferase Reporter Assay
system and measured by luminometer (Promega).
Western blotting and immunohistochemistry
Whole cell lysates were extracted from mouse liver or cul-
tured HEK 293 cells by homogenization in 500 ll of radio-
immunoprecipitation assay buffer (10 mmol/l Tris,
150 mmol/l NaCl, 1 mmol/l EDTA, 1% Nonidet P-40, 01%
sodium dodecyl sulphate [SDS]) and protease inhibitor cock-
tail (1:200 dilution; Sigma Aldrich). The homogenates were
centrifuged at 1000 9 g at 4°C for 5 min. Nuclear protein
from cells and tissues was extracted using the NE-PER
nuclear and cytoplasmic extraction kit (Thermo Fisher Scien-
tific, Loughborough, UK) according to the manufacturer’s
instructions. Protein was quantified using a protein assay
(BioRad, Hemel Hempstead, UK) and resolved using pre-cast
10-12% reducing SDS polyacrylamide gel electrophoresis
(SDS-PAGE; BioRad) before transfer to polyvinylidene diflu-
oride (PVDF) membrane using a Trans blot Turbo (BioRad).
Anti-ATOH8 and anti-DDK (FLAG) (Origene technologies)
and pSMAD 1,5,8 (Cell Signaling Technology, Danvers, MA,
USA) were used to detect the respective proteins. SMAD1
(Santa Cruz Biotechnology, Heidelberg, Germany) or beta
actin (Sigma-Aldrich) were used as controls for protein load-
ing. Blots were visualized by chemiluminescence (Thermo
Fisher Scientific, Loughborough, UK). Immunohistochemis-
try was performed on cryostat sections of mouse liver as pre-
viously described (Patel et al, 2012) using anti-ATOH8 and
fluorescein isothicyanate- conjugated secondary (Dako, Ely,
UK). Sections were counterstained with propidium iodide
(Vector Laboratories, Peterborough, UK) and images cap-
tured using Leica LS-2 confocal microscope (Leica Microsy-
tems, Milton Keynes, UK).
Quantitative polymerase chain reaction (qPCR)
One microgram of total liver RNA was reverse transcribed
using a Transcriptor High Fidelity cDNA kit (Roche Diag-
nostics). All primers were designed using Universal Probe
Library system (Roche Diagnostics) and qPCR was per-
formed using an ABI PRISIM 7900 HT PCR machine
(Applied Biosystems, Paisley, UK). Results were normalized
to the housekeeping RNA Rpl19. Fold change was calculated
using the method of Livak and Schmittgen (2001). In the
case of HAMP, qPCR (Fig 1B) results were normalized to
the housekeeping RNA RPL19 expressed as the negative of
DcT. Details of primer sequences used are presented in
Table SI.
Chromatin immunoprecipitation (CHIP) assays
Chromatin immunoprecipitation assays were performed
using a commercially available kit (Thermo Fisher Scientific).
Chromatin DNA was prepared from untransfected HEK 293
cells and cells transfected with ATOH8-FLAG following the
manufacturer’s protocol and immunoprecipitated using Anti-
FLAG antibody (Origene technologies, Rockville, MD, USA).
PCR (40 cycles) was performed using the primers (5′
CCAGTTACCAGAGCCACATC 3′ and 5′ CAGGAGTGTCTG
CATGTTG 3′), generating a 176 bp fragment encompassing
the E-box 1 and 2 region (Fig 1A). Control PCRs were per-
formed using 10% of the input DNA.
Statistical analysis
Data are presented as means  SD. Statistical differences
were determined using SPSS (IBM, Portsmouth, UK) where
appropriate using either 1-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test or two-tailed Students
t-test. 2-way analysis of variance (2-way ANOVA) was used to
test for significance between two or more groups and Bonfer-
roni post-hoc test for interactions. A P value of <005 was
considered as significant.
Results
ATOH8 regulates HAMP transcription and pSMAD1,5,8
levels in vitro
To test whether ATOH8 could play a role in regulating
HAMP transcription, HEK-293 cells were transfected with
increasing amounts of an ATOH8-FLAG tagged expression
plasmid. Endogenous HAMP mRNA levels were increased by
up to fourfold (P < 0006) following transfection with
increasing amounts of ATOH8-FLAG (Fig 1B). In accord
with this, HAMP promoter activity was increased by around
20- fold (P < 0001) in cells transfected with ATOH8
(Fig 1C) and 09-kb of the human HAMP promoter fused to
the luciferase gene (Fig 1A). In both cases the effect of
ATOH8 was dose-dependent.
We next investigated the effect of mutation of the two
E-box elements within the HAMP promoter previously shown
to bind other bHLH proteins (Bayele et al, 2006). Mutation of
the internal dinucleotide within the E-box elements from
5′-CACGTG-3′ to 5′-CAAATG-3′ (Fig 1A) abolishes nuclear
factor binding(Chen et al, 2012). Mutation of both E-boxes
attenuated ATOH8-dependent HAMP promoter activity by
N. Patel et al
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more than 50% (P < 0001) when compared to the WT pro-
moter treated with ATOH8 (Fig 1C). In addition, mutation of
the BMP response element (BMP-RE) resulted in a 50%
(P < 0001) reduction in ATOH8 dependent HAMP promoter
activation compared to WT treated with ATOH8 (Fig 1C). To
provide evidence for promoter occupancy by ATOH8 we per-
formed CHIP assays using HEK 293 cells transfected with
ATOH8-FLAG. Using the Anti-FLAG antibody as the immu-
noprecipitation (IP) antibody we were able to amplify a
176 bp band encompassing the E-box 1 and 2 regions of the
HAMP promoter from cells transfected with ATOH8-FLAG
but not untransfected cells (Fig 1D).
We next investigated whether ATOH8 transfection affected
pSMAD 1,5,8 levels in HEK 293 cells. ATOH8 transfection
significantly increased pSMAD 1,5,8 levels (P = 0001,
Fig 2C) in a dose-dependent fashion (Fig 2A,B). Hence,
ATOH8 appears to regulate HAMP in two ways, firstly by
acting directly on the HAMP promoter via E-boxes and indi-
rectly through increased pSMAD1,5,8 levels. This may
explain why mutation of E-boxes does not fully repress
HAMP promoter activity.
Regulation of hepatic ATOH8 levels in mouse models
with altered erythropoietic activity
We confirmed the significant down regulation of Atoh8 in
liver of Tfrhpx/hpx mice by qPCR (P = 0001, Fig 3A). In
addition, reduced ATOH8 protein was evident by both Wes-
tern blotting and immunohistochemistry (Fig 3B,C) in
Tfrhpx/hpx mice compared to controls. Thus it appears that
ATOH8 upregulation by iron was overridden in Tfrhpx/hpx
mice in a similar fashion to regulation of liver Hamp1 levels.
We reasoned that the reduction in ATOH8 in Tfrhpx/hpx
mouse liver may be driven by increased erythroid activity.
Treatment of rats or mice with PHZ leads to increased eryth-
ropoietic rate and suppression of Hamp1 usually after a lag
period of 3 d (Frazer et al, 2004; Latunde-Dada et al, 2006;
Masaratana et al, 2012). In mice injected with PHZ there
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was an approximate 27-fold increase in the percentage of
blood reticulocytes (Raja et al, 1989), reduced or absent
serum iron and a 2–3 fold increase in liver non-haem iron.
In normal mice (C57BL/6/129 mixed background) sacrificed
3 d after PHZ treatment, ATOH8 protein levels decreased by
around eightfold (P = 0001, Fig 4A,B) while Atoh8 mRNA
levels were reduced by around twofold (P > 0018) (Fig 4C).
We considered the possibility that ATOH8 may be regulated
downstream of Hamp1, however similar reductions in
ATOH8 protein and mRNA levels were observed in
Hamp1/ mice treated with PHZ (Fig 4A,B,C), suggesting
that regulation of ATOH8 is upstream of Hamp1. The
response of liver ATOH8 protein and mRNA levels to PHZ
was also similar in CD1 and C57BL/6 mice and in both male
and female mice (data not shown). Smad7 and Id1 levels
were suppressed by PHZ treatment in control and Hamp1/
mice, however the decrease was only statistically significant
in the case of Smad7 (Fig S1). Thus in another model with
increased erythropoiesis and liver iron loading, hepatic
ATOH8 levels followed the same downward direction as
Hamp1.
Given that PHZ injection results in other effects, such as
release of haem and increased oxidative stress, we investi-
gated the effects of other more physiological modulators of
erythropoiesis, such as exposure of mice to hypoxia and EPO
injection on liver Atoh8 levels. In mice, EPO injection and
exposure to hypoxia lead to increased erythropoiesis and
suppression of liver Hamp1 mRNA (Nicolas et al, 2002a; Pak
et al, 2006). On the other hand, injection of the cytotoxic
agent carboplatin, which inhibits erythropoiesis, results in
increased liver Hamp1 (Pak et al, 2006; Bartnikas et al,
2010). As previously shown, we found that liver Hamp1
mRNA was suppressed by EPO treatment and increased by
carboplatin treatment (Fig S2A). EPO treatment significantly
reduced liver Atoh8 mRNA levels by around twofold com-
pared to control mice (P = 001), whereas mice treated with
carboplatin alone or EPO and carboplatin had significantly
higher Atoh8 mRNA levels (P < 001) compared to control
or EPO-treated mice (Fig 5A). Mice treated with carboplatin
alone showed the highest induction of Atoh8 mRNA levels
(approximately fourfold induction, P < 0001).
Serum iron levels generally tracked liver Atoh8 levels
(Fig 5B) although some of the treatments did not reach sta-
tistical significance (EPO treatment and EPO with carbopla-
tin). There was a significant correlation between serum iron
and Atoh8 mRNA levels when all experimental groups were
taken together (R2 = 070, P = 0013, n = 19, Fig 5C). Liver
non-haem iron concentration was not significantly affected
by EPO or carboplatin treatments alone but increased signifi-
cantly with carboplatin and EPO treatment (P < 0001,
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Fig S3) and there was no correlation between liver iron
concentration and Atoh8 mRNA levels (R2 = 041, P = 007,
n = 15). Liver Id1 and Smad7 mRNA levels were not affected
by EPO treatment although levels of both were increased by
carboplatin treatment (Fig S4). In contrast to Atoh8 and
Hamp1, Id1 and Smad7 levels were increased further by
carboplatin plus EPO treatments (Fig S4).
Hypoxia is a well-known physiological stimulator of eryth-
ropoiesis that is known to suppress liver HAMP levels in
both mice and man (Nicolas et al, 2002a; Talbot et al, 2012).
Exposure of mice to 24 or 72 h hypoxia reduced liver Atoh8
mRNA levels by around threefold (P < 0001, Fig 5D). Thus,
Atoh8 was regulated by altered erythropoietic activity in the
same direction as Hamp1 and hepatic Atoh8 mRNA levels
correlated with serum iron.
Holo-transferrin has a direct effect on liver Atoh8
mRNA levels
Holo-transferrin is thought to be a key regulator of liver
Hamp1, therefore we investigated whether diferric transferrin
had any direct effect on liver Atoh8 mRNA levels. C57BL/6
mice were treated with 10 mg of holo-transferrin via i.p
injection and sacrificed 6 h later, a treatment previously
shown to increase liver Hamp1 levels without changing liver
iron (Ramos et al, 2011). As previously shown (Ramos et al,
2011) liver Hamp1 mRNA levels were significantly induced
by holo-transferrin but not apo-transferrin (Fig S2B). Treat-
ment of mice with holo-transferrin resulted in an approxi-
mate twofold increase in Atoh8 mRNA levels (P = 0037)
whereas apo-transferrin had no effect (Fig 5E). Serum iron
increased in holo-transferrin injected mice although this did
not reach statistical significance (P = 011, Fig 5F). There
was no significant effect of holo- or apo-transferrin on liver
non-haem iron levels (Fig S3) or on hepatic Smad7 and Id1
mRNA levels (Fig S4A,B). Thus serum levels of diferric trans-
ferrin can directly regulate liver Atoh8 mRNA levels.
Discussion
This study establishes ATOH8 as a novel candidate transcrip-
tional regulator of hepatic HAMP levels and cellular
pSMAD1,5,8 levels. ATOH8 stimulated HAMP transcription
while mutation of E-boxes within the HAMP promoter atten-
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Fig 5. Effect of Hypoxia, EPO, Carboplatin
and Transferrin on liver Atoh8 mRNA levels.
(A) qPCR shows relative Atoh8 levels (normal-
ized to Rpl19; plotted fold-change relative to
control). Control (saline-injected; n = 7), EPO
(n = 4), carboplatin (CARB; n = 4) and EPO
and Carboplatin injected mice (EPO + CARB;
n = 4). (B) serum iron levels in treated mice.
(C) Correlation between serum iron and Atoh8
mRNA in all mice (Pearson correlation coeffi-
cient, R2 = 070, P = 0013, n = 19). (D) qPCR
of liver Atoh8 mRNA levels in control (norm-
oxia) and in mice exposed to hypoxia for 24
and 72 h (Atoh8 levels normalized to Rpl19,
plotted as fold-change relative to control) (E)
Atoh8 levels in control (saline injected)
(n = 7), Holo-transferrin (n = 4) or
Apo-transferrin (n = 4) (Atoh8 levels normal-
ized to Rpl19; plotted as fold-change relative to
control) (F) serum iron levels in treated mice.
Data are presented as mean  SD. Statistical
comparisons were made using 1-way ANOVA
with Tukey’s post hoc test.
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uated ATOH8-dependent HAMP transcriptional responses and
CHIP assays provided additional evidence that ATOH8 binds
to these E-boxes both in vivo and in vitro. Although MYC,
MAX, USF1 and 2 can bind the same E-boxes in vitro (Bay-
ele et al, 2006), the physiological role of these proteins in
iron metabolism in vivo remains unclear. In the case of USF1
and 2 with the well-known exception of a Usf2 knockout
mouse in which the Hamp1 locus was also disrupted (Nicolas
et al, 2001), selective knock out of either Usf1 (Nicolas et al,
2001) or Usf2 (Nicolas et al, 2002b) in mice has no effect on
liver Hamp1 levels or iron metabolism. Furthermore, analysis
of the published array data supplied by Kautz et al (2008)
for iron loaded and iron deficient mouse liver (Data available
at the National Center for Biotechnology Information
[NCBI] Geo database (Edgar et al, 2002), accession
GSE10421) in C57 and DBA strains shows that liver Usf1
mRNA was not iron-regulated in either strain whereas Usf2
mRNA was decreased by iron loading in both strains of mice
but also decreased in iron deficiency. In the HPX mouse
liver, we found no change in Usf1 and an increase in Usf2
mRNA levels (data not shown). In contrast, hepatic Atoh8
and Hamp1 mRNA levels correlated in vivo in mice over a
wide range of conditions of altered iron metabolism (iron
overload, iron deficiency, hypotransferrinaemia, hypoxia,
PHZ, EPO and carboplatin treatment). Moreover, downregu-
lation of ATOH8 by increased erythropoietic drive occurred
in Hamp1 null mice, a scenario consistent with ATOH8
being an upstream regulator of Hamp1. In vivo, there is likely
to be competition between the various E-box proteins for
binding to the HAMP promoter and which protein binds
would depend on hepatic expression levels, DNA binding
affinity as well as other tissue and gene-specific factors. At
present it is unclear what the nature of the higher molecular
weight bands found on ATOH8 liver Western blots (Figs 3B
and 4A) are, however they appear to be regulated in the
same manner as the 37 kDa ATOH8 band. bHLH proteins,
such as MYC and MAX homo or heterodimerize with each
other in order to bind DNA (Blackwell et al, 1993). It is pos-
sible that these higher molecular weight bands are SDS-resis-
tant dimers with other bHLH proteins although further work
will be required to identify these.
ATOH8 also regulated pSMAD1,5,8 levels, providing an
additional mechanism by which ATOH8 could influence
HAMP levels. This was supported by the finding that muta-
tion of the BMP-RE in the HAMP promoter also attenuated
ATOH8-dependent HAMP transcription. It has been sug-
gested that increased erythropoietic activity in mice after
PHZ treatment can attenuate BMP6 signalling and decrease
liver Hamp1 levels without any change in pSMAD1,5,8 levels
(Frazer et al, 2012). We speculate that the reduction in liver
ATOH8 as observed following acute PHZ treatment could
negate the effect of increased BMP6 levels on pSMAD1,5,8,
levels and reduce E-box-dependent transcriptional activation
of HAMP.
Previous work has established that hypoxia and EPO sup-
presses HAMP indirectly through stimulation of erythropoie-
sis while inhibition of erythropoiesis with carboplatin leads
to increases in HAMP (Pak et al, 2006; Talbot et al, 2012).
Liver Atoh8 levels responded to these stimuli in a similar
manner and direction to HAMP, suggesting Atoh8 responds
to the same systemic cues as HAMP. What these cues are
remains to be fully elucidated.
Transferrin saturation correlates directly with erythropoi-
etic activity (Frazer et al, 2004) while numerous studies in
vivo show that serum diferric transferrin levels correlate with
liver Hamp1 levels in mice (Wilkins et al, 2006; Bartnikas
et al, 2010; Li et al, 2010; Ramos et al, 2011). It is thought
that increased diferric transferrin levels leads to stabilization
of TfR2, possibly due to binding of Hfe (Robb & Wessling-
Resnick, 2004; Schmidt et al, 2008), generating an as yet
unidentified signal leading to increased HAMP levels. Our
data, showing that that holo-transferrin also directly regu-
lates liver Atoh8 levels, suggest that this signalling pathway
may involve ATOH8 (Fig 6). However ATOH8 levels were
also suppressed in Hamp1/ mice after PHZ treatment
where plasma iron remains high in the former (Masaratana
et al, 2012) Thus it is possible that other as yet unidentified
erythroid factor (s) released from rapidly developing
erythrocytes or the bone marrow also regulate Atoh8 levels
(Fig 6). Interestingly, hepatic Atoh8 levels were not increased
in Hfe knockout mice, in contrast to other iron loaded
models (Kautz et al, 2008, 2009). This indicates that HFE
may also be required for regulation of ATOH8. Further
work is required to uncover the link between iron sensing
molecules and ATOH8.
To date, none of the other factors known to be involved
in BMP signalling, including BMPs2, 4 and 9, Alk2
(ACVR1), Alk3 (BMPR1A), Hjv (HFE2) and TMPRSS6,
have been shown to be iron-regulated or regulated by
changes in erythropoietic activity in vivo. SMAD7 is a
known inhibitor of the BMP signalling pathway while ID1
is an HLH transcription factor of unknown function, which
acts as a dominant negative inhibitor of other bHLH pro-
teins (Pesce & Benezra, 1993) because it lacks a basic DNA
binding domain but can still form heterodimers (Langlands
et al, 1997; Bounpheng et al, 1999). SMAD7 and ID1 are
iron regulated (Kautz et al, 2008) and therefore could influ-
ence HAMP transcription under increased erythropoietic
activity. However, given that levels of both Smad7 and Id1
mRNA decreased in livers of mice treated with PHZ,
and were unaffected by holo-transferrin or EPO treatments,
its seems unlikely that either are of major impor-
tance in HAMP suppression under enhanced erythropoietic
drive.
BMP6 has been dubbed the iron stores regulator as several
studies have suggested that tissue iron rather than serum iron
is the dominant regulatory factor for BMP6 (Ramos et al,
2011; Frazer et al, 2012). Recently, it has been revealed that
liver Hamp1 levels increased markedly in Bmp6 knockout
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mice following chronic iron loading, indicating other path-
ways in addition to BMP6 are involved in the regulation of
Hamp1 by iron (Ramos et al, 2011). A plausible explanation,
based on our data, is that the effects of iron on Hamp1
expression in the absence of BMP6 are mediated by stimula-
tion of the Atoh8 pathway. Thus BMP6 may modulate
Hamp1 in response to changes tissue iron whereas Atoh8
may regulate responses to serum iron and/or changes in
erythropoietic activity that dominate under certain circum-
stances. Given that ATOH8 affects at least two pathways
which regulate HAMP transcription (BMP signalling and
E-Box dependent transcription) ATOH8 could have a strong
influence hepatic Hamp1. This would allow Hamp1 responses
to various stimuli, explaining how suppression occurs by
increased erythropoietic activity even in the face of liver iron
loading and increased BMP6 levels.
In summary, we identify ATOH8 as a novel transcriptional
regulator of HAMP via two independent mechanisms: E-box
dependent transcriptional activation; and regulation of cellu-
lar pSMAD1,5,8 levels. The regulation of liver ATOH8 levels
observed in mice with altered erythropoiesis suggests ATOH8
as a novel physiological regulator of HAMP. ATOH8 may
link erythropoietic activity and iron-sensing molecules to
HAMP transcription and will open up new avenues of
research leading to improved therapies and management of
iron overload disorders, such as haemochromatosis and
b-thalassaemia.
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